Biomarker Data in Melanoma Presented at ASCO 2018 Are Largely Extensions of Previous Studies Rather Than New Discoveries

Sanjiv S. Agarwala, MD

Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library

Dr Sanjiv Agarwala argues that much of the biomarker data in melanoma presented at ASCO 2018 are around the value of PD-L1 testing; however, even PD-L1–negative melanoma patients seem to respond to anti–PD-1 therapy, although some studies suggest PD-L1–negative patients may be better candidates for combination immunotherapy.

September 2, 2015

Maintenance Setting

Dixie-Lee Esseltine, MD and George Mulligan, PhD discuss the challenges in the current standards of care of patients with multiple myeloma in the maintenance setting.

July 29, 2015

Introducing New Agents into the Standard of Care

Dr. S. Yosuf Zafar questions how to incorporate new agents into the standard of cancer care as many of these agents are both expensive and only useful for a small segment of patients.